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Meta-analysisPurpose: We conducted a systematic review and meta-analysis to quantify the pathological complete
response (pCR) rate after preoperative (chemo)radiation with doses of P60 Gy in patients with locally
advanced rectal cancer. Complete response is relevant since this could select a proportion of patients
for which organ-preserving strategies might be possible. Furthermore, we investigated correlations
between EQD2 dose and pCR-rate, toxicity or resectability, and additionally between pCR-rate and
chemotherapy, boost-approach or surgical-interval.
Methods and materials: PubMed, EMBASE and Cochrane libraries were searched with the terms ‘radiother-
apy’, ‘boost’ and ‘rectal cancer’ and synonym terms. Studies delivering a preoperative dose of P60 Gy
were eligible for inclusion. Original English full texts that allowed intention-to-treat pCR-rate calculation
were included. Study variables, including pCR, acute grade P3 toxicity and resectability-rate, were
extracted by two authors independently. Eligibility for meta-analysis was assessed by critical appraisal.
Heterogeneity and pooled estimates were calculated for all three outcomes. Pearson correlation
coefﬁcients were calculated between the variables mentioned earlier.
Results: The search identiﬁed 3377 original articles, of which 18 met our inclusion criteria (1106
patients). Fourteen studies were included for meta-analysis (487 patients treated withP60 Gy). pCR-rate
ranged between 0.0% and 44.4%. Toxicity ranged between 1.3% and 43.8% and resectability-rate between
34.0% and 100%. Pooled pCR-rate was 20.4% (95% CI 16.8–24.5%), with low heterogeneity (I2 0.0%, 95% CI
0.00–84.0%). Pooled acute grade P3 toxicity was 10.3% (95% CI 5.4–18.6%) and pooled resectability-rate
was 89.5% (95% CI 78.2–95.3%).
Conclusion: Dose escalation above 60 Gy for locally advanced rectal cancer results in high pCR-rates and
acceptable early toxicity. This observation needs to be further investigated within larger randomized
controlled phase 3 trials in the future.
 2014 Elsevier Ireland Ltd. Radiotherapy and Oncology 113 (2014) 1–9 This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Colorectal cancer is the third most common cancer and often
diagnosed in an advanced stage. Treatment of locally advanced rec-
tal cancers (LARC) then consists of neoadjuvant chemoradiation
therapy (CRT) followed by total mesorectal excision (TME). The
clinical outcome after CRT is largely dependent on tumor response
to CRT [1,2]. Overall, 15% of patients experience a pathological
complete response (pCR) at the standard radiation dose
(45–50.4 Gy) [1,3]. Complete response is relevant since this could
select a proportion of patients for which organ-preserving
strategies might be possible, either by local excision ([4,5],ISRCTN14422743) or a ‘‘wait-and-scan’’ strategy [6–8]. Since
response to radiotherapy is dose dependent in rectal cancer, dose
escalation may lead to higher complete response rates [9–11]. A
recent mathematical prediction model on pCR-rate indicated that
50% of patients could reach pCR after 92 Gy and that response
exponentially increased after 60 Gy [12]. This was in line with a
prediction-curve based on a large systematic review on dose
response in patients with LARC [3,12]. Nevertheless, dose-
escalation trials using P60 Gy have not been systematically
reviewed yet. Therefore, we conducted a systematic review and
meta-analysis to quantify the pCR-rate after preoperative
(chemo)radiation with doses ofP60 Gy in patients with LARC. Fur-
thermore, correlations between pCR-rate, acute gradeP3 toxicity,
chemotherapy, boost technique and surgical interval were studied.
2 Impact of radiotherapy boost on pathological complete response in rectal cancerMethods
Search strategy
The PRISMA guidelines for systematic review and meta-analysis
were used to conduct this review [13]. We searched the electronic
PubMed, EMBASE and Cochrane databases with the last search per-
formed on April 10th 2014. Synonym terms for ‘radiotherapy’,
‘boost’ and ‘rectal cancer’ were used (see Supplement). The search
was limited to articles published after 1988, because adjuvant
treatment became progressively replaced by neo-adjuvant
(chemo)radiation since. Duplicates were removed and additional
papers were retrieved through cross referencing.Study selection
All studies in primary LARC patients (T3-4NxM0/ﬁxed tumors)
receiving a preoperative physical radiation dose of P60 Gy (with
at least 45 Gy external beam radiation therapy (EBRT)) to the
whole tumor were eligible for inclusion. Original researches, in
English, with available full texts were included. Studies without
our primary endpoint, palliative intent, or with previously irradi-
ated patients were excluded, as well as studies using contact radio-
therapy and/or X-ray treatment (CXR).Data extraction and quality assessment
The primary outcome was the proportion of patients scheduled
for preoperative P60 Gy radiation that reached pCR. pCR was
deﬁned as absence of residual cancer cells in the resected
specimen. This was calculated by intention-to-treat i.e. the number
of patients with pCR divided by all patients scheduled for preoper-
ativeP60 Gy radiation. If not so provided by the authors, pCR-rate
was calculated from the data. Corresponding authors were
contacted in case of insufﬁcient information.
Secondary outcomes were acute grade P3 toxicity, and
resectability rate. All toxicity scores were redeﬁned to the National
Cancer Institute’s (NCI) Common Terminology Criteria for Adverse
Events (CTCAE v4.0) [14], and presented as the percentages of
patients experiencing acute grade P3 toxicity. Resectability rate
was deﬁned as the percentage of patients with resectable tumors
after (chemo-)radiation divided by all patients scheduled for
preoperative P60 Gy radiation. Furthermore, we extracted study-
design, -size, demographics, the radiation protocol (total dose
(EQD2-dose with alfa/beta = 10 [12]), boost dose, radiation
approach, margins, chemotherapy regimen (agent(s), administra-
tion protocol and doses), and time-to-surgery. Extraction was
performed by two authors independently (J.P.M.B. and A.M.dH.).
In case of discrepancy consensus was reached between authors.Critical appraisal
Study quality was assessed by pre-deﬁned criteria (Table 2)
based on items listed in the Strengthening the Reporting of Obser-
vational Studies in Epidemiology (STROBE) statement [15]. Also
study design, data presentation, and clinical characteristics that
may have inﬂuenced the primary outcome were used. Quality
assessment was also performed independently by two authors
(J.P.M.B. and A.M.dH.). Studies were eligible for meta-analysis if
at least a valid pCR-rate could be calculated.Statistical methods
The R statistical environment (version 3.0.2, R Development
Core Team, 2011) with ‘metafor’ package (version 1.9-1) was used
for statistical analysis [16]. Potential publication bias was checkedby funnel plots and rank correlation tests (Kendall’s tau). pCR-rate,
grade P3 toxicity and resectability rate were logit transformed,
pooled, re-transformed and presented as proportions with 95%
conﬁdence interval (CI). Heterogeneity was assessed by the I2
statistic (i.e. estimated proportion of unexplained inter-study var-
iance) prior to pooling. Random effects models, using a restricted
maximum likelihood estimator, were used in case of large inter-
study variance (I2P 65%) to calculate a pooled estimate. Otherwise
mixed- (25 < I2 < 65%) or (625%) ﬁxed effects models were used.
Robustness of the pooled estimate was addressed by two sensitiv-
ity analyses (SA). The ﬁrst SA excluded studies with pCR-rates
lower than the 15% which we took as a reference standard based
on large meta-analyses [1,3], i.e. negative outliers. The second SA
only included studies with an EQD2-dose of P60 Gy. Correlations
between EQD2-dose and pCR-rate, toxicity and resectability, as
well as between pCR-rate and chemotherapy, boost-approach
and surgical-interval were visualized in scatter plots and formally
tested by Pearson’s correlation test. P-values were considered
signiﬁcant if the p-value was below 0.05.Results
In total 3377 articles were identiﬁed. After removing dupli-
cates, 2765 articles were screened on title and abstract. Seventy-
one remaining articles were screened on full text, of which 54
were excluded for the following reasons: no full text available
(n = 20), studies not involving patients (n = 4), not including
patients with LARC (n = 10), no curative setting (n = 3), only
included previously irradiated patients (n = 1), preoperative dose
of <60 Gy (n = 5), already included (non-unique) patient-popula-
tion (n = 3), non-English articles (n = 2) and studies without our
primary endpoint pCR (n = 6). One additional article was identiﬁed
by cross-referencing. Finally, 18 studies (1106 patients) were
included for systematic review, consisting of 7 prospective sin-
gle/multiple arm studies, 3 RCTs, 2 NRCTs and 6 phase I/II trials
(see Table 1 and Fig. 1) [17–34]. Five-hundred-thirty-nine patients
(48.7% of identiﬁed patients) were scheduled forP60 Gy radiation
with median of 21 patients per study (range 1–109). Median age
ranged between 42 and 68 years. T-stage was reported in 9 studies
for 342 of 539 patients (63.5%), with range 9.0–100%. Nodal status
was reported in 6 studies for 321 patients (59.6%), with a range of
30.0–89.0%.
Treatment characteristics are summarized in Table 1. Total radi-
ation dose varied between 60 and 75 Gy (EQD2 58.4–66.3 Gy), as
an accumulation of standard EBRT (45–54 Gy) and boost dose
(6–30 Gy). Twelve studies used EBRT only, 6 studies used brachy-
therapy only and two combined EBRT and brachytherapy. A simul-
taneous integrated boost (SIB) approach was used in two studies
whereas four studies used a combination of SIB and sequential
approaches. Target margins were mentioned in all but one study
[21]. Most studies used 3–5 ﬁeld box techniques with almost sim-
ilar elective ﬁelds, predominantly deﬁned by 1–1.5 cm anterior to
the sacral wall, 1–2 cm outside the bony pelvis, the L5-S1 border
and 3–5 cm caudal of the tumor. No studies used Intensity Modu-
lated Radiotherapy (IMRT).
All but two studies administered 5-Fluorouracil (5-FU) based
chemotherapy [21,26], namely 5-FU, Uracil-Tegafur (UFT) or
Capecitabine, at varying doses (see Table 1). Leucovorin was added
in six studies and Oxaliplatin in two.
One study did not report toxicity at all [30]. In the other studies
toxicity was mostly scored according to NCI (10 studies), Radiation
Therapy Oncology Group (RTOG, 2 studies), or Response Evaluation
Criteria in Solid Tumors list (RECIST, one study) criteria. Four
studies did not report speciﬁcally which toxicity criteria were used,
Table 1
Characteristics of the included studies (pSA = prospective single arm study, I/II = phase I/II trial, (N)RCT = (non)randomized controlled trial, BID = bis in die (twice daily), Br HDR = brachytherapy high-dose rate, EQD2 = Equivalent 2 Gy
dose, 5-FU = Fluorouracil, UFT = Tegafur-uracil, Leu = Leucovorin, Oxi = Oxaliplatin, TEGAFOX = Uracil/ftorafur/leucovorin/Oxaliplatin, Cap = Capecitabine, n d.d. = in n daily doses, /d = per day, /wk = per week, SIB = simultaneous
integrated boost, pCR = pathologic complete response).
Author, year Study
design
Total
number
of study
patients
(n)
Unique
boost
treated
patients
(n)
Median
age (yr)
of total
study
population
Fractions
(standard)
Dose
(standard)
(Gy)
Fractions
(boost)
Total
dose
(Gy)
EQD2
dose
(total)
Boost
approach
Boost
timing
Chemo-
therapy
in boost
treated
patients
Chemotherapy dose Maximal
tumor
distance
from
anal
verge
(cm)
T3
(%)
T4
(%)
N+
(%)
Interval to
surgery
(planned/
median)
Resect-
ability
rate
(%)
Percentage
acute grade
P3 toxicity
for P60 Gy
(sub)group
(% grade
3/grade 4)
Number
of pCR
events
(boost
patients
only)
Percentage
pCR (n)
Marks et al., 1993 pSA 52 – 57 31  1.8/22  2.5 45.0 5 x1 60 61–64 EBRT SIB – – 0–3 – – – 4–8/– 100.0 – (–/–) – –
Meade et al., 1995 NRCT 20 1 68 25  1.8 45.0 9  1.8 60 60 EBRT Sequential 5-FU (+Leu) 225 mg/m2 d.d. (+30 mg/m2
d.d.)
– 90.0 10.0 30.0 4–8/– 100.0 100 (–/100) 0 0.0
Movsas et al., 1998 I/II 27 7 61 25  1.8 45.0 14  1.2
BID
62 60 EBRT Sequential 5-FU 1000 mg/m2/d for 4 days in
weeks 1 and 4
12 78.0 32.0 – 4–6/– – 85.7 (71.4/
14.3)
– –
Mohiuddin et al., 2000* NRCT 33 9 64 38  1.2 BID 50.0 12  1.2
BID
60 56 EBRT Sequential 5-FU 225 mg/m2 d.d. – – – – 6–8/– 77.0 33 (33/0) 4 44.4
Rouanet et al., 2002* pSA 43 36 64 18  2.1 37.8 10.5  2.1 60 60 EBRT Sequential – – 6 84.0 16.0 30.0 2/– 100.0 – (–/–) 7 16.3
Pfeiffer et al., 2005* I/II 18 14 65 27  2 48.6 3  2 60 60 EBRT SIB + sequential UFT + Leu 150–300 mg/m2/
d + 22.5 mg/d
– – – – 6/5.7 78.0 5.6 (5.6/0) 1 7.1
Jakobsen et al., 2006* pSA 50 50 61 27  2 54.0 3  2; 5
Br HDR
65 66 Brachy Sequential UFT + Leu 100 mg/m2 3 d.d. + 7.5 mg 3
d.d.
10 100.0 0.0 70.0 –/– 96.0 6.0 (6.0/0) 13 26.0
Mohiuddin et al., 2006* RCT 106 16 57 38  1.2 BID 45.6 12  1.2
BID
60 56 EBRT SIB 5-FU 225 mg/m2 d.d. 9 71.0 29.0 – 4–10/7 92.0 42.6 (–/–) 5 31.3
Movsas et al., 2006 II 22 21 64 25  1.8 45.0 14  1.2
BID
62 60 EBRT Sequential 5-FU 1000 mg/m2/d for 4 days in
weeks 1 and 6
12 9.0 91.0 – 4–6/– 100.0 13.6 (–/–) 0 0.0
Ho-Pun-Cheung et al.,
2007
pSA 70 29 64 25  1.8 45.0 9  1.8 60 60 EBRT Sequential – – – – – – 10/– – – (–/–) – –
Sun Myint et al. 2007 pSA 16 16 – 25  1.8 45.0 1  10 Br
HDR
75 61 Brachy Sequential 5-FU / Cap 750/1000 mg/m2 for 4 days
in weeks 1 and 5 or 825 mg/
m2/d
– – – – 6–8/– – – (–/–) 7 43.8
Jakobsen et al., 2008* pSA 35 35 65 27  2 54.0 3  2; 5
Br HDR
65 66 EBRT + Brachy Sequential UFT + Leu 100 mg/m2 3 d.d. + 22.5 mg
3 d.d.
10 77.0 33.0 77.0 8/– 94.2 5.7 (5.7/0) 7 20.0
Vestermark et al., 2008* II 52 36 60 27  2 48.6 3  2 60 60 EBRT SIB + sequential UFT + Leu 100 mg/m2 3 d.d. + 22.5 mg
3 d.d.
– – – – 6/7.9 75.0 5.3 (5.3/0) 3 8.3
Lindebjerg et al., 2009* MA 135 8 65 27  2 60.0 3  2 + 5
Br HDR
60–65 66 EBRT + Brachy SIB + sequential 5-FU + Leu 100 mg/m2 3 d.d. + 22.5 mg
d.d.
10 – – – 8/– 100.0 – (–/–) 1 12.5
Maluta et al., 2010 II 76 76 60 25  2 50.0 5  2 60 60 EBRT Sequential 5-FU + Oxi 200 m/m2/d + 45 mg/m2/wk 12 89.0 11.0 54.0 4–6/– 100.0 1.3 (1.3/0) 18 23.7
Jakobsen et al., 2012* RCT 243 109 63 28  1.8 50.4 2  5 Br
HDR
60 62 Brachy Sequential UFT + Leu
(Denmark) or
5-FU (Canada)
100 mg/m2 3 d.d. + 22.5 mg
3 d.d. (Denmark) or 225/mg/
m2/d (Canada)
10 84.0 16.0 89.0 8/– 92.6 10 (10/0) 20 18.3
Vestermark et al., 2012* I 18 16 62 27  2 48.6 3  2 60 60 Brachy SIB + sequential TEGAFOX
(UFT/Leu/Oxi)
pre-RT 100 mg/m2 3 d.d. +
7.5 mg 3 d.d. on day 1–
14 + Oxi 130 mg/m2.
Concurrent 100 mg/m2 3 d.d.
+ 22.5 mg 3 d.d. + 30–60 mg/
m2/wk increasing with
10 mg/m2/wk
– – – – P6/8.5 – – (–/–) 5 31.3
Engineer et al., 2013 RCT 90 44 42 25  1.8 45.0 11  1.8 65 64 EBRT Sequential – – – – – – 6–8/10 34.0 4.8 (4.8/0) 5 11.4
* Additional data obtained through the corresponding author.
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4 Impact of radiotherapy boost on pathological complete response in rectal cancerbut did report if toxicity demanded treatment. Transformation to
NCI criteria was chosen since it was predominant.
Interval to surgery varied between 2 and 10 weeks (median 7)
after chemoradiation. Resectability ranged between 34.0 and
100%. Five studies reached 100% resectability [18,21,25,30,31].
Others ranged between 75.0 and 96.0% and one was limited to
34.0% [34]. Three studies did not report resectability rate. Most
common reasons to omit surgery were disease progression, distant
metastasis or patient refusal. Surgical complication data were
scarce for theP60 Gy sub(group) speciﬁcally. Six studies reported
wound infection, dehiscence or delayed healing problems in 0.0–
16.0% [21,23,25,29,31,32], one patient required small bowel resec-
tion [18], and two studies reported surgical complications in all
patients [18,34]. Eight studies used some form of standardized
pathologic response assessment, of which four explicitly used the
Mandard tumor regression grade (TRG) [35].
After critical appraisal 14 studies remained eligible for meta-
analysis, representing 90.4% (487 of 539) of patients (Table 2).
Unexplained inter-study variance (I2) was low for pCR pooling
(0.0%, 95% CI 0.0–84.0%) and intermediate for grade P3 toxicity
and resectability pooling (66.2%, 95% CI 25.5–89.6%, and 80.3%,
95% CI 56.1–92.9%, respectively). Consequently, a ﬁxed effects
model was used to calculate the pCR-rate estimate, and a random
effects model for the gradeP3 toxicity and resectability estimates.
pCR-rate varied considerably between studies, from 0.0 to 44.4%.
The pooled pCR-rate estimate was 20.4% (95% CI 16.8–24.5%) (see
Fig. 2). The funnel plot did not show asymmetry (Kendall’s
tau = 0.07, p = 0.74) [36] (see Supplement). Additionally, the ﬁrst
sensitivity analysis, excluding negative outlier pCR-rates below
15%, estimated the pCR-rate at 22.9% (95% CI 18.7–27.6%) and
the second sensitivity analysis, using only studies with EQD2 doses
of P60 Gy, estimated the pCR-rate at 18.1% (95% CI 13.9–23.2%)
(see Fig. 2).
Acute gradeP3 toxicity for boost patients was reliably reported
in 11 of 18 studies. Data on late toxicity speciﬁcally for boost
patients were scarce and therefore not further discussed in this
paper. Acute toxicity consisted mostly of gastro-intestinal com-
plaints, dermatitis, leukopenia/neutropenia and pain. Grade P3
toxicity was low (610%) in seven studies, higher in three (13.6,
33.0 and 42.6%) and a single-patient study had 100% (see Table 1)
[18]. There was no asymmetry in the funnel plot (Kendall’s
tau = 0.1, p = 0.76) (see Supplement). The acute gradeP3 toxicity
estimate was 10.3% (95% CI 5.4–18.6%) (see Fig. 3). The resectabil-
ity estimate was 89.5% (95% CI 78.2–95.3%) (see Fig. 3).
Total EQD2 dose did not correlate with acute gradeP3 toxicity
(Pearson 0.17, p > 0.62) or resectability (Pearson 0.29, p < 0.33).
pCR-rate was not correlated with total EQD2 dose (Pearson 0.44,
p > 0.88), chemotherapy (5-FU only vs. 5-FU + Oxaliplatin) (Pear-
son 0.06, p > 0.83), boost-approach type (EBRT, Brachy or EBRT/
Brachy combination) (Pearson 0.06, p > 0.85), nor with length of
interval between radiotherapy and surgery (Pearson 0.10, p > 0.74).Discussion
This meta-analysis shows a pCR-rate of 20.4% after preoperative
P60 Gy radiation in patients with LARC, which was associated
with low (10.3%) acute grade P3 toxicity and a high resectability
rate (89.5%). Furthermore, no correlation between pCR-rate and
toxicity, resectability, boost approach, chemotherapy or surgical
interval was found.
The calculated pCR-rate estimate of this meta-analysis is in line
with the prediction of the previously mentioned mathematical and
clinical dose–response prediction models. These models further
predict an exponential pCR-rate increase, i.e. degree of tumor cell
destruction, which occurs after linear dose-escalation above
Fig. 1. Flow-chart of the study selection procedure.
J.P.M. Burbach et al. / Radiotherapy and Oncology 113 (2014) 1–9 560 Gy. This is visualized by their S-shaped dose–response curve
[3,12]. We also showed that dose-escalation P60 Gy yielded
comparable toxicity-rates as observed in direct and indirect control
groups after standard dose [24,32,34,37] or after SIB boost tech-
nique of 55.2 Gy [38]. Wiltshire et al. [11] also found a non-linear
relation between dose-increase and toxicity, since their 40 Gy,
46 Gy, and 50 Gy dose levels were associated with 13%, 4%, and
14% acute grade P3 toxicity, respectively. Although we looked at
a larger dose interval, toxicity remained comparable. None of the
studies included in this meta-analysis used IMRT. However, mod-
ern radiation and/or planning techniques may further contribute
to reduced toxicity due to dose reduction to healthy tissue (espe-
cially bowel-dose) [39]. Furthermore, we observed no confounding
between type of concurrent chemotherapy (or radio-sensitizer)
and pCR-rate. This was also previously illustrated in several studies
that found comparable pCR-rates for different sources of 5-FU
[40–44], or when Leucovorin was added as a synergistic agent
[45]. Neither is there consistent evidence that combination chemo-
therapy of 5-FU with Oxaliplatin [46–50] or Irinotecan [51–53]
signiﬁcantly improved pCR-rates, since only the German CAO/
ARO/AIO-04 trial found 17% vs. 13% pCR (odds ratio 1.40, 95% CI
1.02–1.92; p = 0.038) with and without Oxaliplatin respectively
[54]. Nevertheless, it is evident that these combined therapies
increase acute grade P3 toxicity (mostly gastro-intestinal com-
plaints, dermatitis and peripheral neuropathy). Therefore, we are
conﬁdent that neither chemotherapy type nor its dose inﬂuenced
the pooled pCR-rate estimate, which restrained us from calculating
a biological effective dose for each chemotherapy type and its
dose-level. We excluded studies using contact radiotherapy (CXR)
since dose distribution is considerably different from other radia-
tion methods. However, this technique could be used to deliver
high doses to distal, small (less advanced), well-selected (remain-
ing) lesions. Broad experience shows that CXR can however be
safely combined with external-beam radiotherapy [55–59], and
could improve ‘good response’ rates and sphincter preservation
rates in those tumors [60].
The strength of this study is that it provides a reliable and
robust pCR-rate estimate based on a systematic study selectionand intention-to-treat analysis. Furthermore, the low heterogene-
ity between studies allowed to use a ﬁxed-effects model to calcu-
late a robust pCR-rate estimate, since this is a powerful tool to
reveal a pattern of the true effects-size among more studies. Also,
this could then be compared to a well-based estimate for a ‘control’
population [1,3]. Nevertheless, inter-study pCR variability was
present and most likely depends on case-mix. However, such nota-
ble spread is not only present in our selected ‘boost population’ but
is also present within the identiﬁed control populations presented
by Maas et al. and Sanghera et al. [1,3]. Furthermore, all doses from
different radiation treatments (EBRT-SIB, -sequential or brachy-
therapy) were recalculated to EQD2 doses to provide an optimal
comparison method and dose–response analysis over all
approaches together.
The limitations of this study concern study selection, reporting,
pathological assessment and timing of surgery. Firstly, our critical
appraisal excluded four studies from the meta-analysis because
pCR-rates could not be recalculated from the provided data, lead-
ing to a smaller number of patients to pool. Nevertheless, we do
not expect that those excluded studies would dramatically have
inﬂuenced the pooled pCR-rate estimate since these studies repre-
sented only 9.6% (n = 52) of the original identiﬁed sample of 539
patients. Nor did studies with <60 Gy EQD2-doses inﬂuence pCR-
rate estimates. This robustness was indicated by the small positive
2.5% and negative 2.3% pCR-rate shift after sensitivity analyses that
excluded ‘negative outliers’ or studies with EQD2 doses P60 Gy,
respectively. However, small numbers are unfortunately inherent
to feasibility, dose-ﬁnding and early phase (I–II) trials which leaves
the opportunity to further strengthen the evidence by conducting
larger randomized dose-escalation trials. Secondly, we were not
able to study the association between T- or N-stage and pCR-rates
since for most studies response rate according to T-/N-stage was
not reported. Third, the pCR-rate estimate might still be underesti-
mated since pathologic response could only be obtained from oper-
ated patients. Despite our intention-to-treat analysis, and although
the resectability rate was high, more patients might have experi-
enced a complete response. However, we conservatively assumed
all non-surgical patients to have non-pCR which might be incorrect
Fig. 2. Meta-analysis forest plot of pCR-rates and pooled estimate in comparison to a reference line of control group (14.8%) [3] (pCR = pathological complete response).
6 Impact of radiotherapy boost on pathological complete response in rectal cancer
Fig. 3. Forest plot of available acute grade P3 toxicity and resectability with pooled estimate.
J.P.M. Burbach et al. / Radiotherapy and Oncology 113 (2014) 1–9 7since in some patients surgery was omitted for other reasons such
as a worsened condition, newly diagnosed metastasis or patient’s
refusal. Fourth, the pathologic assessment was different between
studies, and therefore prone to bias. Ten of 14 included studies
standardized assessment, of which 3 explicitly used Mandard’s
score [35]. Others only mentioned that one pathologist assessed
if there was ‘absence of viable tumor cells’ in the specimen. Fifth,
destruction of solitary tumor cells may continue long after termi-
nation of radiotherapy, indicating that timing of surgery impacts
response assessment. Three studies have shown increased pCR-
rates when surgery was postponed from 8 to 11 weeks post-radia-
tion (from 11.5 to 14.0%) [61], and when shorter surgical intervals
are compared to intervals of >6–8, or >7, weeks (from 13.7 to
19.5%, and 16 to 28.0% respectively) [62,63]. A relative risk of
1.42 (1.19–1.68) for pCR was reported for intervals longer than
6–8 weeks as compared to intervals shorter than 6–8 weeks. Nev-
ertheless, in our data we did not see an association between inter-
val-length and pCR-rate, presumably because pCR-rate varied
largely at each interval length with only a few studies availableper interval-length point in the analysis. Such variation is common,
and therefore often observed in systematic reviews on pCR-rates
following CRT [1,3,64]. To further investigate the impact of pro-
longed intervals on pCR-rate and sphincter preservation, several
randomized clinical trials are currently recruiting (GRECCAR6/
NCT01648894 [65] and NCT01037049). Nonetheless, if such pre-
sumed time-effects allow extrapolation to when doses are esca-
lated, pCR-rates and organ-preservation might even further
beneﬁt when longer intervals prove to be safe. Sixth, only a single
study reported interval between radiotherapy and brachytherapy,
which did not allow further meta-analysis. Finally, accelerated
treatment (higher dose per fraction, i.e. simultaneous integrated
boost) increases the biological effective dose which may beneﬁt
response [66,67], especially when tumor-regrowth time is short
[68,69]. Nevertheless, some of these accelerated schedules remain
challenging because of considerable toxicity [19,24,70–72] and
peri/post-operative complications [72,73]. It is likely that such tox-
icity originates from irradiation of surrounding tissues instead of
the tumor, as a result of a previously acquired treatment plan
8 Impact of radiotherapy boost on pathological complete response in rectal cancernot taking into account tumor-shrinkage during the course of radi-
ation. The most optimal schedule for high doses thus remains to be
investigated in the future.
In the future disease monitoring will become progressively
important. To discover that some patients do not respond, and will
thus not beneﬁt from additional radiation, should not be kept until
surgery. Response should rather be monitored all along neo-adju-
vant treatment to prevent over-treatment and create the opportu-
nity to adjust an ongoing treatment. This demands sensitive
response-prediction tools employable concurrently to CRT. Such
a non-invasive method capable of differentiating pathological good
(TRG1–2) from bad/none responders (TRG3–5) early during CRT is
diffusion-weighted MRI (DWI) [74,75]. At the same time, this cre-
ates opportunity to identify those tumors likely to beneﬁt from a
sequential radiation boost. Whereas the oncological outcome ben-
eﬁt for patients that reach pCR seems favorable, contradictory out-
comes have been published after reaching a near pCR, ranging from
good prognosis (comparable to pCR) [2,76,77] to poor prognosis
(comparable to poor pathological response) [78–81]. For these
patients, with a proven radiation-sensitivity but near complete
response, early response-assessment could form a future tool to
select them to undergo additional boost radiation in order to fur-
ther improve their response toward a cCR, which is in turn associ-
ated with better prognosis and anticipated improved quality-of-
life if followed by an organ-preservation strategy.
Dose escalation above 60 Gy for locally advanced rectal cancer
results in high pCR-rates and acceptable early toxicity. This obser-
vation needs to be further investigated within larger randomized
controlled phase 3 trials in the future.
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